Abiopharma

DUPONT DE NEMOURS, INC. AND QNITY ELECTRONICS, INC. ANNOUNCE OFFERING OF SENIOR SECURED NOTES AND SENIOR NOTES

New Form 8-K - Immunovant, Inc. Filed: 2025-08-11 AccNo: 0001764013-25-000128 Size: 247 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits

Fennec Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 14, 2025

New Form ARS - Lantern Pharma Inc. Filed: 2025-08-11 AccNo: 0001641172-25-022896 Size: 2 MB

New Form 8-K - BIOCRYST PHARMACEUTICALS INC Filed: 2025-08-11 AccNo: 0001171843-25-005265 Size: 187 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

New Form 8-K - Kymera Therapeutics, Inc. Filed: 2025-08-11 AccNo: 0000950170-25-106227 Size: 451 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits

New Form 6-K - I-Mab Filed: 2025-08-11 AccNo: 0001778016-25-000004 Size: 121 KB

Cardiol Therapeutics to Participate in Fireside Chat at Canaccord Genuity’s 45th Annual Growth Conference

New Form 8-K - Humacyte, Inc. Filed: 2025-08-11 AccNo: 0001818382-25-000122 Size: 366 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits

New Form 6-K - GSK plc Filed: 2025-08-11 AccNo: 0001654954-25-009314 Size: 49 KB

New Form 424B5 - ASSEMBLY BIOSCIENCES, INC. Filed: 2025-08-11 AccNo: 0001193125-25-177435 Size: 636 KB

I-Mab Completes Enrollment in Planned Phase 1b Dose Expansion Study for Givastomig in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers

New Form SCHEDULE 13G - ARROWHEAD PHARMACEUTICALS, INC. Filed: 2025-08-11 AccNo: 0000093751-25-000436 Size: 8 KB

Roivant Reports Financial Results for the First Quarter Ended June 30, 2025, and Provides Business Update

BioXcel Therapeutics to Participate in Canaccord Genuity 45th Annual Growth Conference